This review (2016) compares MDMA with other stimulant drugs with regard to their social effects. The authors conclude that MDMA produces distinct effects in a variety of domains.
±3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug that enhances sociability and feelings of closeness with others. These “prosocial” effects appear to motivate the recreational use of MDMA and may also form the basis of its potential as an adjunct to psychotherapy. However, the extent to which MDMA differs from prototypic stimulant drugs, such as dextroamphetamine, methamphetamine, and methylphenidate, in either its behavioral effects or mechanisms of action, is not fully known. The purpose of this review is to evaluate human laboratory findings of the social effects of MDMA compared to other stimulants, ranging from simple subjective ratings of sociability to more complex elements of social processing and behavior. We also review the neurochemical mechanisms by which these drugs may impact sociability. Together, the findings reviewed here lay the groundwork for better understanding the socially enhancing effects of MDMA that distinguish it from other stimulant drugs, especially as these effects relate to the reinforcing and potentially therapeutic effects of the drug.
Psychostimulant drugs generally produce euphoria, stimulation and increased sociability, but ±3,4-methylenedioxymethamphetamine (MDMA) has been emphasised as having unusually prosocial or ‘‘empathogenic’’ effects. Historical reports and early psychotherapeutic use in the 1970s led researchers to propose that MDMA might form a distinct pharmacological class, and later human laboratory studies since the 1990s have begun to characterise its psychosocial effects relative to other stimulants. Bershad and colleagues set out to review human laboratory findings comparing MDMA with prototypic stimulant drugs (for example d-amphetamine, methamphetamine and methylphenidate) across a range of social domains. The review focuses on placebo-controlled, double-blind studies of healthy volunteers and considers self-report measures, behavioural and physiological tasks, social interaction paradigms, and neurochemical mechanisms, with the aim of identifying which social effects—if any—are distinctive to MDMA and how pharmacology might explain them.
Papers cited by this study that are also in Blossom
Bedi, G., Cecchi, G. A., Slezak, D. F. et al. · Neuropsychopharmacology (2014)
Bedi, G., Hyman, D., De Wit, H. · Biological Psychiatry (2010)
Bershad, A. K., Weafer, J. J., Kirkpatrick, M. G. et al. · Social Neuroscience (2016)
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
The investigators identified relevant papers through two complementary approaches: keyword searches in PubMed and Google Scholar, and examination of reference lists from retrieved articles. Search terms included combinations of "human," "MDMA," "psychostimulants," "social," "emotion," and the names of prototypic stimulants, among others. Inclusion criteria required studies to involve healthy human volunteers and to assess acute drug effects on socio-emotional function using subjective, behavioural, physiological or neural outcomes. The authors summarised the selected studies in a table (not reproduced here). The review is a narrative synthesis rather than a formal systematic review or meta-analysis; the extracted text does not report a date range for searches, a formal risk-of-bias assessment, or quantitative pooling methods.
Self-report effects: Across laboratory and naturalistic reports, MDMA reliably increases self-ratings of sociability, friendliness and positive mood in a dose-dependent manner, with clear prosocial reports at doses around 1.0–1.5 mg/kg. Several subjective effects appear more prominent for MDMA than for classic stimulants: increases in feelings of closeness, trust and openness have been frequently reported. Prototypic stimulants such as d-amphetamine and methamphetamine also increase self-reported sociability, talkativeness and stimulation (e.g. at modest oral doses of 10–20 mg), but the MDMA literature emphasises more intimate interpersonal feelings. Evidence about whether MDMA reduces social anxiety is mixed: one study found that 1.5 mg/kg decreased social anxiety while increasing general anxiety on visual analog scales, and the authors note that classic stimulants more often increase anxiety. MDMA has also been reported to increase feelings of authenticity and self-acceptance; comparable measures have not been widely studied with other stimulants. Social perception and emotional processing: Studies assessing responses to social images and facial expressions indicate differential effects between MDMA and other stimulants. MDMA increased positive ratings specifically for positive social images from the IAPS while decreasing positive ratings for non-social positive images in one study; by contrast, d-amphetamine produced more general enhancement of positive emotional responses regardless of social content. On empathy measures, MDMA (e.g. 75–125 mg) increased emotional empathy (both explicit "feel for" and implicit arousal), especially for positive situations in several studies, whereas methylphenidate (40 mg) did not increase emotional empathy in a reported comparison. Findings on cognitive empathy (emotion identification tasks) are mixed: MDMA often biased identification away from negative expressions and/or enhanced recognition of positive expressions, while d-amphetamine or methylphenidate tended to enhance emotion identification more broadly, including negative emotions. Physiological and neuroimaging evidence aligns with this pattern: MDMA (1.5 mg/kg) increased positive facial EMG responses to happy faces, attenuated amygdala responses to angry faces and enhanced ventral striatal responses to happy faces. By contrast, amphetamine amplified EMG responses to negative stimuli and potentiated amygdala responses to fearful and angry faces. Sexual and arousal responses: In one direct comparison, methylphenidate increased arousal ratings and viewing time for erotic images, whereas MDMA did not affect these measures. This pattern matches user reports that MDMA increases emotional closeness more than sexual desire and some animal data suggesting transient disruption of copulatory behaviour under MDMA. Social rejection and acceptance: Using the Cyberball exclusion paradigm, MDMA (0.75 and 1.5 mg/kg) reduced the negative mood and self-esteem consequences of simulated social rejection and at the higher dose increased the estimated number of throws received during rejection, suggesting both affective dampening and altered perception of social feedback. No acute amphetamine data on this task were reported in the extracted text. Speech and verbal content: Both MDMA and prototypic stimulants increase subjective talkativeness, but objective speech effects differ. d-Amphetamine and methamphetamine increase speech quantity and fluency, whereas MDMA did not increase speech production and may decrease verbal fluency. MDMA (1.5 mg/kg) increased the social and emotional content of spontaneous speech, including greater use of positive-emotion and social words and semantic proximity to concepts like "friend," "support" and "intimacy." Methamphetamine did not produce the same increase in social content in a reported comparison. Trust, reciprocity and resource allocation: Some evidence suggests MDMA increases trust and prosocial allocations: MDMA (125 mg) increased prosocial choices on the Social Value Orientation Task, and 1.0 mg/kg increased willingness to allocate money to a friend over oneself on the Welfare Trade-Off Task. Naturalistic self-report studies also link ecstasy use to greater perceived trustworthiness of faces and cooperative behaviour, though such studies often lack drug confirmation and control for concomitant substances. Other laboratory tasks yielded null findings for trust or reciprocity under MDMA. Comparable measures have rarely been reported for classic stimulants, limiting direct comparison. Social interaction and context effects: MDMA alters perceptions of live social partners, increasing feelings that a research assistant understood or was interested in participants, and improving comfort when discussing autobiographical memories. Social context modulates MDMA's effects: administration in the presence of another participant augmented physiological and subjective drug responses, whereas presence of a research assistant did not. For d-amphetamine, comparable studies showed increased physiological responses when tested with others but typically no change in subjective effects, suggesting social settings enhance MDMA's subjective sociability more than they do for other stimulants. Mechanistic findings: Pharmacologically, classic stimulants act primarily via dopamine and norepinephrine release with lesser effects on serotonin, while MDMA preferentially increases serotonin and norepinephrine and induces dopamine release more indirectly. Human and animal studies implicate serotonergic, noradrenergic and peptidergic systems in MDMA's social effects. MDMA elevates peripheral oxytocin in humans and one study reported a correlation between peak oxytocin and self-reported social effects; genetic variation in the OXTR gene (rs53576) was also reported to moderate sociability responses to MDMA in one study. Methamphetamine does not appear to elevate oxytocin, supporting a possible oxytocinergic contribution to MDMA-specific effects. Oxytocin and vasopressin interactions are discussed, with some rodent evidence that vasopressin receptors contribute to prosocial effects. Human pharmacological challenge studies produced mixed results: 5-HT1A antagonism with pindolol had little effect (possibly due to inadequate receptor occupancy), SSRIs variably attenuated aspects of MDMA's subjective profile, and agents affecting norepinephrine (reboxetine, duloxetine) reduced particular social items such as closeness, openness and talkativeness. Overall, the evidence supports roles for both serotonin and norepinephrine, and possibly oxytocin/vasopressin, in MDMA's prosocial effects, but the precise pathways and their relevance relative to classic stimulants remain incompletely characterised.
Bershad and colleagues conclude that MDMA exhibits both shared and distinctive social effects compared with prototypic stimulants. Shared effects include increased friendliness, some changes in verbal behaviour and enhanced positive responses to stimuli, whereas MDMA appears to be more selective in increasing trust, generosity, emotional empathy, positive appraisal of social stimuli and social/emotional content in spontaneous speech. Neuroimaging and physiological data suggest MDMA reduces neural responses to negative social cues (for example attenuated amygdala reactivity) and enhances responses to positive social cues, a pattern that differs from amphetamine. The authors caution that relatively few studies directly compare MDMA with classic stimulants and that dose equivalence across drugs is difficult to establish. They note other limitations inherent to the literature: many investigations are tightly controlled laboratory studies that may not capture naturalistic social contexts; self-report measures depend on the vocabulary and insight of participants; and participant drug-use history varies across studies and may influence responses. Methodological gaps include sparse direct comparisons on some behavioural paradigms, limited replication of mechanistic findings (for example the oxytocin correlation) and mixed results from pharmacological blockade studies. Regarding implications, the review highlights that MDMA's capacity to dampen responses to negative social stimuli and to enhance feelings of closeness and trust could plausibly underlie both its recreational appeal and its potential as an adjunct in psychotherapy, for example by strengthening therapeutic alliance and modifying processing of traumatic memories. The authors recommend further controlled comparisons between MDMA and prototypic stimulants, more ecologically valid studies of social interaction, and mechanistic work to clarify the neurotransmitter and peptide systems mediating MDMA's prosocial effects. They also indicate interest in examining MDMA's effects on memory and reconsolidation processes in therapeutic contexts.
Psychostimulant drugs produce feelings of euphoria and stimulation, as well as increasing confidence and enhancing social interaction. One stimulant drug in particular, ±3,4-methylenedioxymethamphetamine (MDMA, "ecstasy," "molly"), is known for its unusual prosocial and "empathogenic" subjective effects, and for its potential use as an adjunct to psychotherapy. In the 1970s, MDMA was used to facilitate self-awareness and empathy during psychotherapy. Even after the drug became illegal in the USA in 1985, recreational use of MDMA increased steadily, especially in a dance-music culture that was arguably influenced by the drug's unusual effects. In the mid-1980s, based on the structureactivity relationships of MDMA-like molecules,proposed that the psychosocial effects of MDMA represented a novel pharmacological class, which he named "entactogens" to capture its apparently unique sensory and emotional effects. Data from rodent drug-discrimination paradigms (reviewed insuggested that MDMA was clearly distinguishable from hallucinogens, but shared many pharmacological, discriminative, and behavioral effects with prototypic amphetamine-like stimulants. Finally, in the 1990s, researchers began to conduct controlled studies to measure the psychosocial effects of MDMA in humans and to compare these to the effects of other stimulants. This review complements a recent paper by Kamilar-Britt andwho comprehensively reviewed empirical studies of the psychosocial effects of MDMA. Here, we extend that overview by focusing on the contrasts between MDMA and prototypic stimulant drugs.concluded, based on about 30 published studies, that MDMA has "prosocial" effects and that it dampens reactivity to negative emotional stimuli. Here, we extend that analysis to examine possible differences between MDMA and prototypic stimulant drugs in order to identify which subjective and behavioral effects are unique to MDMA, and how the mechanism of action of the drug may explain these effects. One of the apparently distinctive effects of MDMA is that it enhances sociability and interpersonal closeness, which may contribute to both recreational use and potential therapeutic use. Inducing a state of sociability and interpersonal closeness may allow psychotherapy patients to explore negative emotions and cognitions, such as traumatic memories related to post-traumatic stress disorder. Interestingly, classic stimulant drugs also produce prosocial effects and were historically also proposed as adjuncts to psychotherapy. Thus, although MDMA purportedly has distinctive effects, the empirical basis for this has not been examined closely. Here, we review these drugs' effects on self-report ratings, behavioral tasks, and social interactions in placebo-controlled, double-blind studies in human volunteers. We also review preclinical and clinical studies investigating the potential neurochemical mechanisms of the observed prosocial effects. Our goal is to determine the extent to which the effects of MDMA are distinct from approved and widely studied drugs such as amphetamine. Unfortunately, because relatively few studies have examined the effects of classic stimulant drugs on socio-emotional processing, less is known about these effects, relative to MDMA. Few studies have directly compared the two. Another challenge is determining doses that are comparable for each drug. Throughout this review, we have made an effort to note and discuss the comparability of doses of MDMA compared to other stimulants, when appropriate. The aim of this review is to improve the understanding of the nature and mechanisms of how MDMA and other stimulants produce their psychosocial effects and how these effects contribute to both recreational use and potential therapeutic value.
Relevant articles for this review were selected via two methods. First, PubMed and Google Scholar searches were conducted using a combination of search terms, including "human," "MDMA," "psychostimulants," "stimulants," "social," "emotion," "methamphetamine," "methylphenidate," "d-amphetamine," and "mechanism." Second, additional articles were selected from the reference lists of the articles obtained from the searches if they (1) included a sample of healthy human volunteers and (2) assessed the acute effects of drugs on some aspect of socio-emotional function, including subjective, behavioral, physiological, and neural outcomes. The results are summarized in Table.
Much of our knowledge about the effects of MDMA and other psychostimulants comes from self-reports of users; either retrospective reports from recreational users or reports obtained during controlled administration in laboratory studies. These self-report measures provide some of the primary evidence for the prosocial effects of the drugs. Early evidence about MDMA, based on MDMA users' recall of their experiences in naturalistic settings, consistently suggests that this drug produces powerful prosocial effects.found that 68% of users reported "enhanced communication, empathy, or understanding."surveyed university students who had used MDMA, and found the most common effect reported was a heightened sense of "closeness" with others. There are, to our knowledge, no corresponding naturalistic studies of social effects of other stimulants such as methamphetamine. However, there are quite a number of placebo-controlled laboratory-based studies confirming that both MDMA and other stimulants increase feelings of sociability. MDMA dose-dependently increases ratings of sociability, euphoria, and positive mood. MDMA at doses of 1.0-1.5 mg/kg, but not lower doses, produces feelings of friendliness and sociability (e.g.. Similarly, modest oral doses (10-20 mg) of prototypic stimulants such as dextroamphetamine (d-amphetamine) and methamphetamine enhance self-reported positive mood and increase self-reports of feeling "social," "stimulated," "friendly," and "talkative". However, several subjective effects appear to be unique to MDMA, including increases in feelings of "closeness," "trust," and "openness", suggesting that the drug may have distinctive effects on intimate interaction. Interestingly, a recent study showed that lysergic acid diethylamide (LSD; 200 μg), which, like MDMA, has important serotonergic activity, increased ratings of trust, openness, and closeness to others. This similarity suggests that the unique effects of MDMA among stimulants on these feelings of connection may be related to its effects on serotonin. Although these findings are suggestive of qualitative differences in subjective interpersonal feelings between MDMA and other stimulants, one caution is that researchers have not specifically sought to test for these effects with prototypic stimulants, leaving the possibility that they may exist. One psychological process whereby a drug might increase feelings of sociability is by decreasing social anxiety. For example, MDMA may increase feelings of social connectedness by dampening anxiety in social settings. However, evidence that the prosocial effects of MDMA are secondary to a general anxiolytic effect is mixed. In fact, MDMA sometimes produces modest increases in anxiety (e.g., and participants report feeling impaired in some aspects of social or cognitive functioning. It is possible that MDMA specifically dampens social anxiety versus other forms of anxiety. In support of this idea,reported MDMA (1.5 mg/kg) decreased social anxiety (measured with the Brief Fear of Negative Evaluation) while also increasing visual analog scores for general anxiety. There is little evidence that other stimulant drugs, such as amphetamine, decrease anxiety, and indeed they can increase anxiety. Notably, although few studies have examined the effects of classic stimulant drugs specifically on social anxiety, we recently reported that d-amphetamine does not decrease social anxiety induced by a standardized public-speaking task. Whether either MDMA or other stimulants have selective effects on other forms of social anxiety remains to be determined. Another psychological process by which MDMA may produce its effects is by increasing feelings of "authenticity." Authenticity is a construct with roots in humanistic psychology, which refers to the feeling of being connected to one's inner being rather than to external demands. It is associated with lessened defensiveness and feeling that one is able to be oneself. Using the Authenticity Index,recently reported that MDMA increases feelings of authenticity, including related feelings such as self-regard and self-acceptance. These findings are consistent with a recent naturalistic self-report study indicating that illicit ecstasy preparations increase self-compassion. To our knowledge, these dimensions of authenticity have not been studied with typical stimulant drugs, although it has been reported that positive mood can increase feelings of authenticity. It therefore remains to be determined whether MDMA affects this feeling state in a way that differs from typical stimulants.
Another way of assessing "prosocial" effects of drugs is to measure how the drug affects the perception or processing of social stimuli. Several studies have investigated the acute effects of MDMA and other simulants on aspects of social perception. These studies, summarized here, suggest that both MDMA and other stimulants alter the ways in which individuals respond to social and sexual visual stimuli, as well as the degree to which they recognize emotions in the faces of others (i.e. "cognitive empathy"). Other studies have investigated the effect of MDMA on the experience of social rejection.
Several studies have examined the effects of both MDMA and other stimulants on ratings of positivity or negativity of images depicting social or nonsocial scenes. Some of these studies addressed the hypothesis that MDMA produces its prosocial effects by increasing positive responses to positive social stimuli, and dampening negative responses to negative social stimuli.measured MDMA (0.75 mg/kg, 1.5 mg/ kg) effects on ratings of positive and negative, social and nonsocial images from the International Affective Picture System (IAPS). MDMA increased how positively participants rated positive social images (i.e. those depicting people), but decreased how positively they rated positive images without social content. The drug did not alter ratings of negative or neutral images, whether social or non-social. In contrast, d-amphetamine (10 mg, 20 mg) enhanced positive emotional responses in general, but its effects were not specific to stimuli with social content. This provides some evidence that MDMA may selectively alter how people process social, compared to nonsocial, rewards. The effects of MDMA and other stimulants on social perception have also been studied using measures of empathy. Empathy has been defined as either "empathic concern," that is, an individual's emotional response to the emotional state of another, or a more cognitive measure, that is, the ability to detect emotions in others. Empathic concern has been assessed using the Multifaceted Empathy Test in which participants view images of emotionally charged situations, and report how much they "feel for" each person depicted (explicit emotional empathy), and how "aroused" they feel (implicit emotional empathy;.reported that MDMA (125 mg) modestly increased both explicit ("feel for") and implicit ("aroused") emotional empathy for positive situations, especially in men.replicated these findings at a lower dose (75 mg), andfound that MDMA increased emotional empathy for both positive and negative emotional situations. Of the few of studies that compared the effects of MDMA to a classic stimulant,reported that methylphenidate (40 mg) did not increase ratings of emotional empathy for positive situations. Thus, while there have been slight inconsistencies across studies, MDMA appears to increase emotional empathy, especially for positive situations, and these effects have not been reported for other stimulant drugs. Inconsistencies across studies may be related to variations in the drug use histories of the participants;recruited poly-drug MDMA users, while the other two studies recruited subjects with light drug-use histories, most of whom were MDMA-naïve. Althoughreported that the drug use history has little effect on subjective responses to MDMA, it remains possible that prior drug use has subtle effects on responses to MDMA. Other studies have examined the effects of drugs on the cognitive component of empathy, which involves inferring the mental states of others. This is usually measured by asking participants to identify the emotion expressed in images of faces, such as the Reading the Mind in the Eyes Taskor the Facial Emotion Recognition Task. Facial expressions are potent social cues that signal how others are feeling, and thus may guide appropriate social responses. Changes in detection of emotions could affect social behavior by increasing sensitivity to positive expressions or blunting responses to negative expressions (for a review, see. The findings from the studies with MDMA are mixed, but tend to show that MDMA acts differentially on identification of positive and negative expressions. In some cases, MDMA enhanced identification of positive emotions and reduced identification of negative emotions, whereas in other studies, MDMA selectively reduced responses to negative emotional expressions without altering responses to positive faces. In contrast, d-amphetamine (20 mg) enhanced the ability to identify both positive and negative emotional expressions on the emotion identification task, and methylphenidate (60 mg) enhanced the ability to identify negative emotional expressions. These findings suggest that prototypical stimulant drugs such as d-amphetamine may act in a non-selective way, or even a negative way, to enhance emotion identification, while MDMA tends to bias emotion identification in a positive direction. Some of these conclusions are tempered by concerns about possible response biases with different emotional expressions. Happiness, for example, is easier to identify in many stimulus sets, and it may be the case that MDMA selectively impairs identification of the more difficult to identify expressions first. Responses to emotional stimuli can also be measured using physiological or neural assessments. Facial electromyography (EMG), for example, assesses subtle facial movements indicative of positive and negative emotional responses, arguably at a lower threshold than self-report measures.found that 1.5 mg/kg (approx. 105 mg) MDMA increased positive EMG responses to happy faces. In a functional magnetic resonance imaging,reported MDMA (1.5 mg/kg) attenuated amygdala activity during presentation of angry faces, and enhanced ventral striatum activity during presentation of happy faces. The ventral striatum is activated during reward anticipation of both social and nonsocial reward, and the amygdala is involved in the processing of threat-related information. In contrast to the effect of MDMA,found that amphetamine magnified EMG responses to negative emotional stimuli, andshowed that amphetamine potentiated amygdala responses to fearful and angry faces. Thus, by these measures, there are clear differences between classic stimulants and MDMA. Interestingly, the serotonergic hallucinogen psilocybin (0.16 mg/kg) appears to have similar effects on amygdala reactivity as MDMA, dampening responses to negative emotional faces. Taken together, these findings indicate that MDMA has distinctive effects on emotional processing compared with amphetamine at the neural level. These findings help to explain why MDMA reduces social anxiety (i.e. by reducing responses to negative or threatening social stimuli and increasing responses to positive stimuli), and may also lend support for the idea that these effects are partly a result of the drug's serotonergic activity. In addition to emotional responses to social stimuli, one study investigated the effects of both MDMA (75 mg) and methylphenidate (40 mg) on arousal responses to sexual stimuli. In this study, subjects viewed and rated explicit erotic images, and pressed a button to increase image presentation time. Interestingly, methylphenidate increased arousal ratings and increased the average time participants chose to spend viewing implicit erotic images, whereas MDMA did not affect either of these measures. These findings suggest that classic stimulants, but not MDMA, increase desire for sexual contact. This is consistent with a rodent study showing that MDMA produced a transient disruption in male copulatory behavior, and with user reports emphasizing increased emotional closeness and openness to sexual activity rather than sexual desire per se.
Responses to social cues can also be assessed using actual positive and negative social experiences. One potent social experience is exclusion or rejection by others, as modeled in the computerized virtual ball-tossing game called Cyberball.used Cyberball to measure the effects of MDMA on perceptions of social rejection and acceptance. In the game, players are first "accepted" and then "rejected" by other "players" (i.e. the participant either receives many throws or very few throws from the other, computer-controlled players;. Participants then rate their emotions during the game and estimate the number of throws received. Rejection in the game reliably increases negative mood and reduces self-esteem.reported that MDMA (0.75 and 1.5 mg/kg) reduced the effects of simulated social rejection on mood and self-esteem, and that the higher dose (1.5 mg/kg) also increased the estimated number of throws subjects received during the rejection condition. Thus, MDMA not only affected mood, but also arguably altered their objectively estimated level of rejection. An interesting secondary observation in this study was that because in the placebo condition participants tended to underestimate the number of throws they received when rejected, MDMA appeared to improve subjects' accuracy of the number of throws they received. This observation is consistent with the possibility that MDMA may also decrease the distortion of negative selfrelevant facts, a phenomenon common in depression. The dampening of social rejection may also contribute to the psychotherapeutic benefits of MDMA by allowing patients to speak freely and openly about their issues. To our knowledge, no studies have yet examined the effects of an acute dose of amphetamine on the social rejection task. Overall, these findings suggest that MDMA attenuates response to negative emotional stimuli and negative social experiences. The extent to which these effects differ from prototypic stimulant drugs has not been fully studied. Decreased responsiveness to negative stimuli would not only make a drug attractive to users who seek to enhance social experiences, but also, in the case of MDMA, may also help patients feel safer and more accepted in psychotherapy.
The psychosocial effects of MDMA and other stimulants have also been assessed by analyzing spontaneous speech production and content. Speech is a crucial component of human social interaction, and drugs can alter many aspects of speech, including self-reports of feeling talkative, speech quantity, production, fluency, and content (Higgins and. Both MDMA and other stimulants such as d-amphetamineincrease self-ratings of talkativeness, although the drugs' effects on actual speech vary. Both d-amphetamineand methamphetamineincrease speech quantity as well as speech fluency (i.e. decreasing the number of silent pauses or "um/uh's" during speaking;. However, MDMA does not affect speech production, and may decrease verbal fluency. Drugs may also affect the degree of synchronization between speakers, and it has been reported that both d-amphetamine and the hallucinogen LSD enhance synchronization of speech between a therapist and patient. Whether MDMA produces this effect remains to be determined. Other studies have investigated the effects of drugs on speech content, providing an indication of mental and emotional states during intoxication. In these studies, participants received a drug and were asked to speak freely about a close personal relationship, for instance a close friend or family member, with a research assistant. Speeches were then analyzed for preselected content categories, such as words pertaining to emotion, social interaction, and cognition. Relative to placebo, MDMA (1.5 mg/kg) increased the use of sexual, social, and emotional wordsand the use of positive emotion words. In a study comparing MDMA and methamphetamine,reported that speech following 1.5 mg/kg of MDMA had greater semantic proximity to concepts of "friend, support, intimacy, and rapport," and 0.75 mg/kg had greater proximity to empathy. By contrast, methamphetamine (20 mg) did not increase the social content of speech. Thus, while both MDMA and prototypic stimulant drugs affect speech, their effects appear to be different, perhaps reflecting the different character of their social effects. Taken together, the evidence reviewed here suggests that stimulant drugs alter speech in ways that are consistent with their effects on social behaviors. Methamphetamine and d-amphetamine increased talkativeness and speech fluency, whereas MDMA appears to increase the emotional and social content of speech. These findings lend support to the idea that MDMA preferentially affects intimate social interaction and emotional openness rather than nonspecifically increasing speech output. Analysis of speech is a promising approach to identify the social processes by which drugs work.
The effect of MDMA on ratings of "trust" and "closeness to others", and its effect on trust decisions, reciprocity, and resource allocation, appear to be unique. MDMA (125 mg) increased prosocial behavior on the Social Value Orientation Task in which participants allocate resources between themselves and others. In a naturalistic study querying users in their normal drug-taking environments,found that self-reported illicit ecstasy use (the presence of MDMA was not confirmed) was associated with increased ratings of trustworthiness of faces and more prosocial decisions on three cooperative behavior tasks. These results are complicated, however, by the lack of information about the other drugs that participants had used, the doses, subjects' expectancies, and the psychosocial context in which they were assessed. In another laboratory-based study,used the Welfare Trade-Off Taskto show that MDMA (1.0 mg/kg; approx. 75 mg) increased participants' willingness to allocate money toward a friend (but not to a stranger) rather than themselves. Interestingly, this differential effect coincides with a report that the neuropeptide oxytocin (discussed below) selectively enhances trust among individual members of a social in-group. Because MDMA potently increases oxytocin, it is tempting to speculate that the effects on MDMA on responses to friends versus strangers are mediated by its effects on oxytocin. However, in other studies, MDMA did not affect resource allocation of trust in the Trust Game, or reciprocity in a ball-tossing game. In summary, there is some evidence that MDMA increases trust and generosity, as measured by resource allocation tasks. To our knowledge, these measures have not been studied with classic stimulant drugs, and future studies should include a prototypical stimulant control condition to be able to tease apart the MDMA-specific effects.
A final behavioral process that has been used to investigate the pro-social effects of drugs is the study of in-person social interaction. Drugs are typically used in social settings, and users of both MDMA and other stimulant drugs report using these drugs to enhance social experiences. The relationship between social interactions and drug taking can be reciprocal: drugs can enrich social interactions and, in turn, the presence of others may heighten the rewarding effects of the drug. To examine the interactive effects of drugs and interpersonal relations, several studies have tested MDMA on perceptions of others, and how the presence of others affects responses to the drug. MDMA can alter perceptions of others during an actual social interaction. Typically in these studies, participants perform a brief speech task with a research assistant and subsequently rate their interaction with the research assistant. In one study, MDMA (1.5 mg/kg) modestly increased the degree to which participants felt the research assistant understood and was interested in them. Interestingly, this effect is distinguishable from reports that the drug increased empathy for others. Here, MDMA increased perceptions of empathy from others. This appears consistent with the report bythat MDMA increased the comfort participants felt when describing autobiographical memories to a researcher. Increased feelings of being understood and accepted by real others provides additional evidence for the drug's benefits in strengthening therapist-patient alliances in psychotherapy settings.examined the effect of MDMA (0.5 and 1.0 mg/kg) in participants who were tested under either social conditions, with another person, or isolated conditions. Participants were tested under three conditions: alone in a room, with a research assistant present, or with another participant who received the same drug. Participants who received MDMA in the presence of another participant showed the greatest increases in physiological responses to the drug (i.e. heart rate) and greater subjective responses of feeling and liking the drug. These effects are consistent with findings that social context can heighten effects of other drugs, including alcohol and benzodiazepines (e.g.. But the findings also suggest that the type of social context matters in affecting acute responses to the drug; that is, the presence of another drug user facilitates responses, whereas the presence of a research assistant does not. Together, these two studies suggest that MDMA not only enhances social situations, but also that its effects are stronger when taken in the presence of others. This may explain why MDMA is so commonly used in social settings. Two studies with similar designs have investigated the effects of social settings on responses to d-amphetamine. In one study, d-amphetamine (10 mg, 20 mg) produced greater physiological responses (heart rate and body temperature) when subjects were tested with other participants compared with alone, although this was not found in an earlier study. Notably, unlike with MDMA, social conditions did not alter the subjective effects of amphetamine in either study. This suggests that social settings enhance the subjective effects of MDMA but not other stimulants.
Classic stimulant drugs such as amphetamine, methamphetamine, and methylphenidate are thought to exert their psychoactive effects primarily by inducing the release of dopamine and norepinephrine, and, to a lesser extent, serotonin. In contrast, MDMA preferentially increases serotonin and norepinephrine releaseand induces dopamine release indirectly as a consequence of serotonergic release. MDMA directly inhibits dopamine reuptake. In a recent review,hypothesized that this high ratio of serotonergic to dopaminergic effects is key for producing MDMA-like effects, and that similar drugs with a lower ratio produce more familiar, prototypic stimulant effects. One study showed that specifically blocking 5HT 2A signaling reduced the positive mood-inducing effects of MDMA without affecting negative mood, which is particularly interesting in light of some of the drug's similar effects to serotonergic hallucinogens such as LSD and psilocybin. While less studied, MDMA also induces acetylcholine releaseand has low micromolar affinity for histamine H1 and muscarinic M1 and M2 receptors. The exact mechanisms by which MDMA produces its unusual prosocial effects are not known, and the drug's complex pharmacology makes this difficult to determine. Studies with humans indicate that both serotonergic and noradrenergic mechanisms are likely important for self-reported social effects. Studies with both rodents and humans suggest that some of the drug's effects are related to release of oxytocin and vasopressin, two structurally related neuropeptides that are known to regulate social recognition and affiliation, anxiety, and aggression. MDMA-induced oxytocin release appears secondary to the drug's serotonergic effects. Released serotonin stimulates 5-HT 1A receptors on hypothalamic oxytocin-containing neurons, inducing release of oxytocin into peripheral blood. Several studies have confirmed that MDMA also elevates peripheral oxytocin in humans. One study reported a correlation between peak oxytocin levels after MDMA and self-reported social effects, although this correlation has yet to be replicated. Another recent study showed that genetic differences in the oxytocin receptor gene (OXTR) may affect feelings of sociability in response to MDMA; that is, individuals homozygous for the A allele at rs53576 did not report enhanced sociability on 1.5 mg/kg of MDMA, unlike G allele carriers. Importantly, methamphetamine does not appear to induce the release of oxytocin, lending weight to the possibility that differing oxytocinergic effects may contribute to differential social effects of MDMA and prototypic stimulants. The downstream mechanisms by which oxytocin contributes to MDMA's effects may also include vasopressin. Exogenous administration of both oxytocin and vasopressin can produce prosocial behavior, an effect that is blocked by a V 1A vasopressin receptor antagonist but not an oxytocin antagonist. This suggests oxytocin in high concentrations may significantly stimulate vasopressin receptors, and raises the possibility that MDMA-induced vasopressin release may contribute to prosocial effects of the drug. MDMA and its metabolites induce vasopressin release from isolated rat hypothalamusand may elevate serum vasopressin (or the co-released copeptin) in humans (e.g.. However, V 1A vasopressin receptor antagonism with SR49059 only partially blocked the prosocial effects of MDMA in rodents, supporting a limited role for this pathway. Several studies with humans have examined effects of drugs that attenuate serotonin or oxytocin function on social effects of MDMA. The 5-HT 1A antagonist pindolol, which would be expected to reduce oxytocin release, had little effect on responses to MDMA. However, this lack of effect may have been due to insufficient receptor occupancy or lack of sensitive "prosocial" measures. Similarly, while pretreatment with a selective serotonin reuptake inhibitor (SSRI) attenuates self-reported effects of MDMA in humans, it is unclear to what extent SSRIs attenuate the social effects of the drug.found that citalopram attenuated MDMA effects on selfreported ratings of self-confidence and extraversion but did not decrease ratings of emotional sensitivity and excitability.reported that paroxetine attenuated MDMA effects on both social and nonspecific measures of euphoria (i.e. very happy, good mood, more positive view about things).found that fluoxetine did not change MDMA effects on self-report ratings of talkative and friendly. In sum, serotonin release likely contributes to some of the self-reported social effects of MDMA in humans, but the extent to which nonserotonergic mechanisms contribute is not fully known. Noradrenergic mechanisms appear particularly likely to be involved in the effects of MDMA. Duloxetine, which inhibits release of both serotonin and norepinephrine, reduced global effects of MDMA and euphoria as well as the visual analog items Closeness, Openness, and Talkativeness. Duloxetine also showed a nonsignificant trend effect on the Reading the Mind in the Eyes Task, suggesting a possible attenuation of MDMA effects on empathy. Further, reboxetine, which inhibits MDMA-induced norepinephrine but not serotonin release, reduced "closeness," but not the other social visual analog items. Overall, this suggests both norepinephrine and serotonin release contribute to the social effects of MDMA in humans, although it is not clear how these mechanisms and effects relate to those of classic stimulant drugs.
Taken together, it appears that MDMA produces distinctive effects that are distinguishable from prototypic stimulants across several social domains, including appraisal of social stimuli and naturalistic social interactions. The evidence reviewed here suggests that compared with typical stimulants, MDMA has both shared and distinctive effects on social processing and social behavior. Prototypic stimulants increases self-reported feelings of friendliness, increase some aspects of verbal behavior, increase positive responses to stimuli (regardless of social or emotional content), and increase sexual arousal. MDMA more specifically increases self-reported feelings of trust and generosity, increases responses to social and emotionally valenced stimuli, increases empathy, and increases the social and emotional themes in spontaneous speech. However, relatively few studies have directly compared MDMA to other stimulants. Because MDMA has generated research interest as a "prosocial" drug and an empathogen, more studies have examined these effects with MDMA than for typical stimulants. Thus, the full constellation of social effects that are truly unique to MDMA remains to be determined. Direct comparisons across drugs will also help to determine the neural substrates for the social psychological processes, including social versus nonsocial reward processes. Most of the studies included in this review are highly controlled laboratory-based investigations into emotion processing. Such studies, while providing insight into basic mechanisms of social processing, may not directly represent more real-world drug-use situations. Beyond the artificiality of the laboratory setting, the paradigms used to investigate drug effects on emotion processing come with their own limitations. Self-report ratings, for example, provide a critical index of the psychological effects of MDMA and prototypic stimulants by providing a rich profile of both the qualitative and quantitative features of the drugs. Arguably, these drug-induced subjective states form the basis for an individual's future decisions about drug use, either recreational or therapeutic. On the other hand, self-report measures also have limitations. Currently, the effects that researchers can detect are limited by the descriptors of mood and social effects that are provided to them, and by the participants' ability to report them accurately. Therefore, there is also an important role for behavioral and physiological measures to quantify the prosocial effects of MDMA. A final consideration is the potential role of these prosocial MDMA effects in psychotherapy. MDMA may strengthen the patient-therapist relationship and alter processing of both external and internally generated emotional stimuli. MDMA may also affect other processes, such as memory or memory reconsolidation. Carhart-showed that participants rated positive memories as more vivid, emotionally intense, and positive following the administration of MDMA (100 mg) compared with placebo. Indeed, it has been suggested that psychotherapy can be viewed as the activation of negative emotional memories within a positively valenced therapeutic context, resulting in reconsolidated of memories in a new, more positive form. These interesting psychological processes, and their distinctness from those that occur under the influence of prototypical stimulant drugs, remain to be studied under carefully controlled conditions.
Create a free account to open full-text PDFs.
Buffum, J., Moser, C. · Journal of Psychoactive Drugs (1986)
Carhart-Harris, R. L., Wall, M. B., Erritzoe, D. et al. · International Journal of Neuropsychopharmacology (2013)
Downing, J. · Journal of Psychoactive Drugs (1986)
Dumont, G., Sweep, F., van der Steen, R. et al. · Social Neuroscience (2009)
Frye, C. G., Wardle, M. C., Norman, G. J. et al. · Pharmacology Biochemistry and Behavior (2014)
Greer, G. R. · Journal of Psychoactive Drugs (1986)
Hasler, F., Ludewig, S. · Journal of Psychopharmacology (2008)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2009)
Kamilar-Britt, P., Bedi, G. · Neuroscience and Biobehavioral Reviews (2015)
Kirkpatrick, M. G., Delton, A. W., de Wit, H. et al. · Journal of Psychopharmacology (2015)
Kirkpatrick, M. G., Lee, R., Wardle, M. C. et al. · Neuropsychopharmacology (2014)
Liechti, M. E., Baumann, C., Gamma, A. et al. · Neuropsychopharmacology (2000)
McElrath, K. · Substance Use and Misuse (2009)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Nichols, D. E. · Journal of Psychoactive Drugs (1986)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Simmler, L. D., Hysek, C. M., Liechti, M. E. · Journal of Clinical Endocrinology Metabolism (2011)
Stewart, L., Ferguson, B., Morgan, C. J. A. et al. · Journal of Psychopharmacology (2014)
Van Wel, J. H. P., Kuypers, K. P. C., Theunissen, E. L. et al. · PLOS ONE (2012)
Wardle, M. C., De Wit, H. · Psychopharmacology (2014)
Zemishlany, Z., Aizenberg, D., Weizman, A. · European Psychiatry (2020)
Papers in Blossom that reference this study
Luoma, J. B., Lear, M. K., Pilecki, B. et al. · Psyarxiv (2026)
Martinez, R. L., Radošić, N., Molla, H. et al. · Journal of Psychopharmacology (2025)
Maples-Keller, J. L., Hyatt, C. S., Phillips, N. L. et al. · Journal of Psychoactive Drugs (2024)
Zacher, A., Zimmermann, J., Cole, D. M. et al. · European Neuropsychopharmacology (2024)
Haggarty, C. J., Bershad, A. K., Kumar, M. K. et al. · European Journal of Neurology (2024)
Netzer, O., Magal, N., Stern, Y. et al. · Biorxiv (2024)
Elmer, T., Vannoy, T. K., Studerus, E. et al. · Scientific Reports (2024)
Bershad, A. K., Hsu, D. T., De Wit, H. · Journal of Psychopharmacology (2024)
Molla, H. M., Lee, R., Lyubomirsky, S. et al. · Scientific Reports (2023)
Kangaslampi, S., Zijlmans, J. · European Child and Adolescent Psychiatry (2023)
Makunts, T., Abagyan, R., Dahill, D. et al. · Frontiers in Psychiatry (2023)
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Nichols, D. E. · Frontiers in Psychiatry (2022)
Sharp, J. L., Smith, M. A. · Frontiers in Behavioural Neuroscience (2022)
Pantoni, M. M., Kim, J. L., Van Alstyne, K. R. et al. · Psychopharmacology (2022)
Maples-Keller, J. L., Norrholm, S. D., Burton, M. et al. · Journal of Psychopharmacology (2022)
Corkery, J. M., Makunts, T., Jerome, L. et al. · Frontiers in Psychiatry (2022)
Regan, A., Margolis, S., De Wit, H. et al. · PLOS ONE (2021)
Luoma, J. B., Lear, M. K. · Frontiers in Psychiatry (2021)
Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
de Wit, H., Bershad, A. K., Grob, C. S. · Journal of Psychopharmacology (2021)
Studerus, E., Vizeli, P., Harder, S. et al. · Journal of Psychopharmacology (2021)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Gorman, I., Belser, A. B., Jerome, L. et al. · Journal of Traumatic Stress (2020)
Bahji, A., Forsyth, A., Groll, D. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020)
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B. et al. · Frontiers in Psychiatry (2019)
Curry, D. W., Berro, L. F., Belkoff, A. R. et al. · Neuropharmacology (2019)
Vizeli, P., Meyer Zu Schwabedissen, H. E., Liechti, M. E. · ACS Chemical Neuroscience (2018)
Ot'alora G, M., Grigsby, J., Poulter, B. et al. · Journal of Psychopharmacology (2018)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Papaseit, E., Torrens, M., Pérez-Mañá, C. et al. · Expert Opinion on Drug Metabolism and Toxicology (2018)
Schmid, Y., Schmidt, A., Müller, F. et al. · International Journal of Neuropsychopharmacology (2017)
Doss, M. K., Weafer, J. J., Gallo, D. A. et al. · Neuropsychopharmacology (2017)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Bershad, A. K., Miller, M. A., De Wit, H. · Psychopharmacology (2017)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)